Prostate Cancer Reports


Volume 1 Supplement 2
 February 2013
Home > Prostate Cancer Reports > Volume 1 - Year 2013 > Supplement 2, February 2013

CONTENTS



Clinical & Lab investigations
Localized PCa
Low-risk PCa



CLINICAL & LAB INVESTIGATIONS


Familiality

Hemminki K, Ji J, Försti A, Sundquist J, Lenner P.
Concordance of survival in family members with prostate cancer.
J Clin Oncol. 2008 Apr 1;26(10):1705-9. doi: 10.1200/JCO.2007.13.3355.
Abstract | Full text | Related citations


Finasteride

Parnes HL, Thompson IM, Ford LG.
Prevention of hormone-related cancers: prostate cancer.
J Clin Oncol. 2005 Jan 10;23(2):368-77.
Abstract | Related citations


Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
J Clin Oncol. 2007 Jul 20;25(21):3076-81.
Abstract | Full text | Related citations


Gleason scoring system

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA.
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
J Clin Oncol. 2009 Jul 20;27(21):3459-64. doi: 10.1200/JCO.2008.20.4669. Epub 2009 May 11.
Abstract | Full text | Related citations


Overviews



Small EJ, de Bono JS.
Prostate cancer: evolution or revolution?
J Clin Oncol. 2011 Sep 20;29(27):3595-8. doi: 10.1200/JCO.2011.37.8653. Epub 2011 Aug 22.
Abstract | Full text | Related citations



Small EJ, Klein EA.
Challenges and Future Directions in the Prevention and Management of Prostate Cancer

JCOvol. 23 no. 32 8143-8145. doi: 10.1200/JCO.2005.10.001
Abstract | Full text


Recurrence



Dale W.
"Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
J Clin Oncol. 2009 Jul 20;27(21):3420-2. doi: 10.1200/JCO.2009.22.9104. Epub 2009 Jun 8.
Abstract | Full text | Related citations



Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M, Stadler WM.
Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
J Clin Oncol. 2009 Apr 1;27(10):1557-63. doi: 10.1200/JCO.2008.18.5850. Epub 2009 Mar 2.
Abstract | Full text | Related citations


Screening

Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE.
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
J Clin Oncol. 2011 May 1;29(13):1736-43. doi: 10.1200/JCO.2010.31.9004. Epub 2011 Mar 28.
Abstract | Full text | Related citations

LOCALIZED PROSTATE CANCER


Mortality

Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV.
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
J Clin Oncol. 2005 Sep 20;23(27):6556-60.
Abstract | Full text | Related citations



Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
J Clin Oncol. 2005 Oct 1;23(28):6992-8.
Abstract | Full text | Related citations


Recurrence



D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
J Clin Oncol. 2005 Aug 1;23(22):4975-9.
Abstract | Full text | Related citations


Patel DA, Presti JC Jr, McNeal JE, Gill H, Brooks JD, King CR.
Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy.
J Clin Oncol. 2005 Sep 1;23(25):6157-62.
Abstract | Full text | Related citations



Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW.
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
J Clin Oncol. 2005 Oct 1;23(28):7005-12.
Abstract | Full text | Related citations


Survival



Brenner H, Arndt V.
Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
J Clin Oncol. 2005 Jan 20;23(3):441-7. Epub 2004 Nov 30.
Abstract | Full text | Related citations



Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz PI.
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
J Clin Oncol. 2007 Aug 20;25(24):3576-81.
Abstract | Full text | Related citations



Wilding G, Remington P.
Period analysis of prostate cancer survival.
J Clin Oncol. 2005 Jan 20;23(3):407-9. Epub 2004 Nov 30.
Abstract | Full text | Related citations

LOW-RISK PROSTATE CANCER


D'Amico AV.
Future of treatment for low-risk prostate cancer: for all, for some, or for none?
J Clin Oncol. 2011 May 20;29(15):1940-3. doi: 10.1200/JCO.2010.34.2006. Epub 2011 Apr 4.
Abstract | Full text | Related citations


Active surveillance

Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR.
Outcomes of active surveillance for men with intermediate-risk prostate cancer.
J Clin Oncol. 2011 Jan 10;29(2):228-34. doi: 10.1200/JCO.2010.31.4252. Epub 2010 Nov 29.
Abstract | Full text | Related citations


Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB.
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
Abstract | Full text | Related citations